Shares of Relypsa Inc (NASDAQ: RLYP) surged higher by more than 30 percent early Friday morning on no corporate news or rumors.
According to the TheStreet'sAdam Feuerstein, Relypisa scored a "big win" on Friday after its chief rival AstraZeneca plc (ADR) (NYSE: AZN) confirmed the U.S. Food and Drug Administration sent a Complete Response Letter (CRL) concerning its hyoperkalaemia treatment known as ZS-9.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Related Link: AstraZeneca Remains Committed To Development Of ZS-9 Despite Letter From FDA
Feuerstein suggested that AstraZeneca's setback is "fantastic news" for Relypsa, who just secured FDA approval for its rival drug Veltassa last October. He also noted that AstraZeneca didn't offer a timeline for when it will attempt to secure FDA approval again which implies Relypsa has the commercial market all to itself.
"With the near-term competitive threat from ZS-9 gone, Relypsa has the opportunity to stake out a commanding lead with Veltassa before AstraZeneca can even get to the starting line," Feuerstein concluded.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.